Literature DB >> 11388968

Neurodevelopmental indices and the development of psychotic symptoms in subjects at high risk of schizophrenia.

S M Lawrie1, M Byrne, P Miller, A Hodges, R A Clafferty, D G Cunningham Owens, E C Johnstone.   

Abstract

BACKGROUND: Neurological 'soft signs' and minor physical anomalies (MPAs) are reported to be more frequent in patients with schizophrenia than in controls. AIMS: To determine whether these disturbances are genetically mediated, and whether they are central to the genesis of symptoms or epiphenomena.
METHOD: We obtained ratings in 152 individuals who were antipsychotic drug-free and at high risk, some of whom had experienced psychotic symptoms, as well as 30 first-episode patients and 35 healthy subjects.
RESULTS: MPAs and Neurological Evaluation Scale (NES) 'sensory integration abnormalities' were more frequent in high-risk subjects than in healthy controls, but there were no reliable differences between high-risk subjects with and without psychotic symptoms. MPAs were most frequent in high-risk subjects with least genetic liability and NES scores showed no genetic associations.
CONCLUSIONS: The lack of associations with psychotic symptoms and genetic liability to schizophrenia suggests that soft signs and physical anomalies are nonspecific markers of developmental deviance that are not mediated by the gene(s) for schizophrenia.

Entities:  

Mesh:

Year:  2001        PMID: 11388968     DOI: 10.1192/bjp.178.6.524

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  24 in total

1.  The Edinburgh High Risk Study: current status and future prospects.

Authors:  Eve C Johnstone; Kirsten D Russell; Lesley K Harrison; Stephen M Lawrie
Journal:  World Psychiatry       Date:  2003-02       Impact factor: 49.548

2.  Neurological soft signs predict abnormal cerebellar-thalamic tract development and negative symptoms in adolescents at high risk for psychosis: a longitudinal perspective.

Authors:  Vijay A Mittal; Derek J Dean; Jessica A Bernard; Joseph M Orr; Andrea Pelletier-Baldelli; Emily E Carol; Tina Gupta; Jessica Turner; Daniel R Leopold; Briana L Robustelli; Zachary B Millman
Journal:  Schizophr Bull       Date:  2013-12-27       Impact factor: 9.306

3.  Cranial Nerves III, IV, and VI: Oculomotor Function.

Authors:  Richard D Sanders
Journal:  Psychiatry (Edgmont)       Date:  2009-11

4.  Do we have any solid evidence of clinical utility about the pathophysiology of schizophrenia?

Authors:  Stephen M Lawrie; Bayanne Olabi; Jeremy Hall; Andrew M McIntosh
Journal:  World Psychiatry       Date:  2011-02       Impact factor: 49.548

5.  Trajectories of social withdrawal and cognitive decline in the schizophrenia prodrome.

Authors:  Kathryn Cullen; Angela Guimaraes; Jeffrey Wozniak; Afshan Anjum; S Charles Schulz; Tonya White
Journal:  Clin Schizophr Relat Psychoses       Date:  2011-01

6.  Minor physical anomalies in schizophrenia: a meta-analysis.

Authors:  Seth M Weinberg; Elizabeth A Jenkins; Mary L Marazita; Brion S Maher
Journal:  Schizophr Res       Date:  2006-10-31       Impact factor: 4.939

Review 7.  Physical manifestations of neurodevelopmental disruption: are minor physical anomalies part of the syndrome of schizophrenia?

Authors:  Michael T Compton; Elaine F Walker
Journal:  Schizophr Bull       Date:  2008-11-05       Impact factor: 9.306

8.  Expanding the schizophrenia phenotype: a composite evaluation of neurodevelopmental markers.

Authors:  John P John; Vikram Arunachalam; Bhuvaneshwari Ratnam; Mohan K Isaac
Journal:  Compr Psychiatry       Date:  2007-10-15       Impact factor: 3.735

Review 9.  Schizophrenia: solving the puzzle.

Authors:  B D Kelly; E O'Callaghan; A Lane; C Larkin
Journal:  Ir J Med Sci       Date:  2003 Jan-Mar       Impact factor: 1.568

10.  Neurological soft signs and their relationships to neurocognitive functions: a re-visit with the structural equation modeling design.

Authors:  Raymond C K Chan; Ya Wang; Li Wang; Eric Y H Chen; Theo C Manschreck; Zhan-jiang Li; Xin Yu; Qi-yong Gong
Journal:  PLoS One       Date:  2009-12-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.